Lupus Science & Medicine

Article	Citations
Genetic load in incomplete lupus erythematosus	153
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study	59
Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis	42
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus	41
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE	36
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes	31
Correction of omega-3 fatty acid deficiency and improvement in disease activity in patients with systemic lupus erythematosus treated with krill oil concentrate: a multicentre, randomised, double-blin	30
Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study	30
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus	30
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology	28
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study	24
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme	24
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	24
Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption	23
Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history	23
Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study	23
Prevalence of coeliac disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis	23
High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus	22
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort	21
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases	21
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice	19
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus	17
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study	17
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study	17
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin	17

B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children	17
Dialogue: Hydroxychloroquine pharmacokinetic (PK) and exposure response in pregnancies with systemic lupus erythematosus: the importance of adherence for neonatal outcome	16
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis	16
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins	16
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	16
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study	15
COVID-19 vaccination questionnaire in patients with systemic lupus erythematosus: an observational study	15
Activation-induced colocalisation of SCAMP5 with IFNα in human plasmacytoid dendritic cells	15
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms	15
Dialogue: Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	15
Comparing dermatologic patient-reported outcome measures in cutaneous lupus erythematosus	15
Immune complex–driven neutrophil activation and BAFF release: a link to B cell responses in SLE	14
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients	14
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus	13
Breastfeeding in women with rheumatic diseases	13
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	13
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria	13
Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE)	12
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	12
Validating claims-based algorithms for a systemic lupus erythematosus diagnosis in Medicare data for informed use of the Lupus Index: a tool for geospatial research	12
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	11
Antiplatelet effects of hydroxychloroquine in patients with systemic lupus erythematosus evaluated by the total thrombus-formation analysis system (T-TAS)	11
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease	11
Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children	11
Cutaneous lupus concerns from the patient perspective: a qualitative study	11
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE	11
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)	11
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	11
Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay andCrithidia luciliaeassay in a multiethnic racial cohort of patients with SLE	10
Altered structural and functional homotopic connectivity associated with cognitive changes in SLE	10
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field	10
Intermuscular adipose tissue in patients with systemic lupus erythematosus	10
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus	10
SARS-CoV-2 vaccines in patients with SLE	10
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol	10
Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review	10
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence	10
Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review	10
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	10
HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis	10
Correction: SARS-CoV-2 vaccines in patients with SLE	10
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	10
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort	10
Molecular signatures of intrarenal complement receptorsC3AR1andC5AR1correlate with renal outcome in human lupus nephritis	9
Higher mortality risk from gynaecological neoplasms and non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry	9
Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study	9
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus	9
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies	9
Circulating extracellular vesicles in Systemic Lupus Erythematosus: physicochemical properties and phenotype	9
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study	9

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	8
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	8
Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education	8
p16Ink4a, a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3mouse model of lupus	8
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity	8
Are patients with systemic lupus erythematosus at increased risk for COVID-19? A bi-directional Mendelian randomisation study	8
CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?	8
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	8
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	8
Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study	8
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand	8
Black patients with cutaneous lupus are associated with positive family history of cutaneous lupus and systemic lupus	8
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis	8
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis	8
Canadian workplace experiences of systemic lupus erythematosus (SLE)	8
Assessment of SLE activity for acute clinical decision-making: use of a colour-coded threat-level approach for the non-rheumatologist	8
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lu	8
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study	8
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	7
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	7
Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data	7
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state	7
Potential involvement of circulating exosomal miRNA-146a in disease activity andTRAF6gene expression in juvenile proliferative lupus nephritis	7
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	7
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	7
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study	7
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus	7
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis	7
Development and validation of a risk scoring system to identify patients with lupus nephritis in electronic health record data	6
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine	6
Herpes zoster in SLE: prevalence, incidence and risk factors	6
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus	6
Clinical trial outcomes for SLE: what we have and what we need	6
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	6
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus	6
Systemic Lupus Erythematosus Risk Probability Index: ready for routine use? Results from a Chinese cohort	6
Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus	6
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance	6
SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus	5
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	5
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory	5
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	5
Curcumin attenuates lupus nephritis by inhibiting neutrophil migration via PI3K/AKT/NF-κB signalling pathway	5
Abnormally high expression of D1-like dopamine receptors on lupus CD4+T cells promotes Tfh cell differentiation	5
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	5
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology	5
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	5
Joint surgery rates in lupus: a long-term cohort study	5
CD4+T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE	5
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study	5
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE	5
Novel potential lncRNA biomarker in B cells indicates essential pathogenic pathway activation in patients with SLE	4
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model	4
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study	4
“There’s so much to be done”: a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus	4
ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies	4
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria	4
Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021	4
Systemic blockade of proBDNF inhibited the expansion and altered the transcriptomic expression in CD3+B220+cells in MRL/lpr lupus mice	4
Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity	4
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis	4
Large overlap in neutrophil transcriptome between lupus and COVID-19 with limited lupus-specific gene expression	4
Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations	4
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	4
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice	4
Development of a predictive model for systemic lupus erythematosus incidence risk based on environmental exposure factors	4
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort	4
Consequences of medication unavailability on patient anxiety: the example of the 2020 hydroxychloroquine availability crisis for patients with SLE – 18 months later	4
Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus	4
Ancestry,ACKR1and leucopenia in patients with systemic lupus erythematosus	4
Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis	4
Use of a screening questionnaire for systemic lupus erythematosus among pregnant women in a Mexican population	4
Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis	4
Investigations intoSCAMP5,a candidate lupus risk gene expressed in plasmacytoid dendritic cells	4
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network	4
Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study	4
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus	4
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks	4
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials	4
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis	3

Topological structural characteristics in patients with systemic lupus erythematosus with and without neuropsychiatric symptoms	3
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts	3
Development and implementation of a virtual Lupus Patient Education Event during the COVID-19 pandemic	3
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	3
Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections	3
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	3
Utility of skin biopsy in patients with systemic lupus erythematosus	3
Myocardial Performance Index to assess cardiac function in autoimmune connective tissue disease: a systematic review and meta-analysis	3
Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study	3
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study	3
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome	3
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	3
Clinical associations of cognitive dysfunction in systemic lupus erythematosus	3
Correction: Differences in reproductive health discussions in an urban hispanic population with SLE: lessons from the field	3
Clinical and histopathological features of myositis in systemic lupus erythematosus	3
Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis	3
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations	3
Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol	3
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	3
Methyl-donor supplementation in women with systemic lupus erythematosus with different nutritional status: the protocol for a randomised, double-blind, placebo-controlled trial	3
Improving routine mental health screening for depression and anxiety in a paediatric lupus clinic: a quality improvement initiative for enhanced mental healthcare	3
Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: does a gold standard dsDNA assay exist?	2
Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE	2
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	2
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA	2
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus	2
Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus	2
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus	2
Frequency of sarcopenia in Turkish women with systemic lupus erythematosus	2
Multidisciplinary re-evaluation of neuropsychiatric events to confirm the neuropsychiatric lupus diagnosis at an Indonesian tertiary hospital	2
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus	2
Phenotypical changes and clinical significance of CD4+/CD8+T cells in SLE	2
5-Hydroxymethylcytosine in circulating cell-free DNA as a potential diagnostic biomarker for SLE	2
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	2
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015	2
Relationship between retinal microvascular impairment and subclinical atherosclerosis in SLE	2
Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor	2
Using photovoice to investigate patient experiences of lupus nephritis in Canada	2
Multiple polygenic risk scores can improve the prediction of systemic lupus erythematosus in Taiwan	2
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials	2
Favourable humoral but reduced cellular immune response to COVID-19 mRNA BNT162b2 vaccine in patients with childhood-onset systemic lupus erythematosus	2
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to ac	2
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research	2
Infection-related hospitalisation in young adults with systemic lupus erythematosus: data from the National Inpatient Sample	2